CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …

Abstract Cytochrome P450 (CYP) family 1, 2, and 3 enzymes play an essential role in the
metabolic clearance and detoxification of a myriad of structurally and chemically diverse …

Small-molecule docking has proven to be invaluable for drug design and discovery.
However, existing docking methods have several limitations such as improper treatment of …

Drug-repurposing technologies are growing in number and maturing. However,
comparisons to each other and to reality are hindered because of a lack of consensus with …

Background Direct oral anticoagulants have been evaluated for their efficacy and safety in
the treatment of venous thromboembolism (VTE), which comprises deep vein thrombosis …

Even though there are a great number of possible conformational states, how a protein
generated as a linear unfolded polypeptide efficiently folds into its physiologically active …

The cytochrome P450s enzyme family metabolizes∼ 80% of small molecule drugs. Variants
in cytochrome P450s can substantially alter drug metabolism, leading to improper dosing …

Tamoxifen is a prodrug and cytochrome P450 2C9 (CYP2C9) has a significant role in the
formation of a therapeutically more potent metabolite (4-hydroxytamoxifen) than tamoxifen …

Cytochrome P450 enzymes (CYPs) represent an important enzyme superfamily involved in
metabolism of many endogenous and exogenous small molecules. CYP2D6 is responsible …

Background The gene polymorphisms of the CYP2C9, as well as the substrate specificity of
the enzyme, result in different clearances for different substrates by CYP2C9 variants …